Cargando…
Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
BACKGROUND: Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. OBJECTIVES: to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hosp...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719379/ https://www.ncbi.nlm.nih.gov/pubmed/34979235 http://dx.doi.org/10.1016/j.phrs.2021.106053 |
_version_ | 1784624925125902336 |
---|---|
author | Caiazzo, Elisabetta Rezig, Asma O.M. Bruzzese, Dario Ialenti, Armando Cicala, Carla Cleland, John G.F. Guzik, Tomasz J. Maffia, Pasquale Pellicori, Pierpaolo |
author_facet | Caiazzo, Elisabetta Rezig, Asma O.M. Bruzzese, Dario Ialenti, Armando Cicala, Carla Cleland, John G.F. Guzik, Tomasz J. Maffia, Pasquale Pellicori, Pierpaolo |
author_sort | Caiazzo, Elisabetta |
collection | PubMed |
description | BACKGROUND: Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. OBJECTIVES: to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hospitalised with respiratory viral infections, including COVID-19, SARS, MERS and influenza. METHODS: We identified randomised trials published prior to July 28th, 2021. The Mantel-Haenszel random effects method and the Hartung and Knapp adjustment were used to obtain pooled estimates of treatment effect with 95% confidence intervals. RESULTS: No randomised trials of glucocorticoids for SARS, MERS or influenza reported relevant outcomes. We included eleven COVID-19 randomised trials (8109 patients). Overall, compared to placebo or standard care, glucocorticoids were not associated with a reduction of in-hospital mortality (p = 0.09). In a pre-specified sub-analysis, in-hospital mortality was reduced by 19% when follow-up was restricted to 14 days from randomisation (5/11 trials, 1329 patients, p = 0.02). With longer follow-up (9/11 trials, 7874 patients), administration of glucocorticoids was associated with a trend to benefit for those requiring mechanical ventilation (RR 0.86; 95% CI 0.57–1.27) but possible harm for those not receiving oxygen at randomisation (RR 1.27; 95% CI 1.00 – 1.61), an effect that was significantly different amongst subgroups (p = 0.0359). Glucocorticoids reduced the risk of worsening renal function by 37% (4/11 trials); reported rate of other cardiovascular complications was low. CONCLUSIONS: Administration of systemic glucocorticoids to patients hospitalised with COVID-19 does not lower mortality overall but may reduce it in those requiring respiratory support and increase it in those who do not. |
format | Online Article Text |
id | pubmed-8719379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87193792022-01-03 Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials Caiazzo, Elisabetta Rezig, Asma O.M. Bruzzese, Dario Ialenti, Armando Cicala, Carla Cleland, John G.F. Guzik, Tomasz J. Maffia, Pasquale Pellicori, Pierpaolo Pharmacol Res Article BACKGROUND: Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. OBJECTIVES: to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hospitalised with respiratory viral infections, including COVID-19, SARS, MERS and influenza. METHODS: We identified randomised trials published prior to July 28th, 2021. The Mantel-Haenszel random effects method and the Hartung and Knapp adjustment were used to obtain pooled estimates of treatment effect with 95% confidence intervals. RESULTS: No randomised trials of glucocorticoids for SARS, MERS or influenza reported relevant outcomes. We included eleven COVID-19 randomised trials (8109 patients). Overall, compared to placebo or standard care, glucocorticoids were not associated with a reduction of in-hospital mortality (p = 0.09). In a pre-specified sub-analysis, in-hospital mortality was reduced by 19% when follow-up was restricted to 14 days from randomisation (5/11 trials, 1329 patients, p = 0.02). With longer follow-up (9/11 trials, 7874 patients), administration of glucocorticoids was associated with a trend to benefit for those requiring mechanical ventilation (RR 0.86; 95% CI 0.57–1.27) but possible harm for those not receiving oxygen at randomisation (RR 1.27; 95% CI 1.00 – 1.61), an effect that was significantly different amongst subgroups (p = 0.0359). Glucocorticoids reduced the risk of worsening renal function by 37% (4/11 trials); reported rate of other cardiovascular complications was low. CONCLUSIONS: Administration of systemic glucocorticoids to patients hospitalised with COVID-19 does not lower mortality overall but may reduce it in those requiring respiratory support and increase it in those who do not. Elsevier 2022-02 /pmc/articles/PMC8719379/ /pubmed/34979235 http://dx.doi.org/10.1016/j.phrs.2021.106053 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Caiazzo, Elisabetta Rezig, Asma O.M. Bruzzese, Dario Ialenti, Armando Cicala, Carla Cleland, John G.F. Guzik, Tomasz J. Maffia, Pasquale Pellicori, Pierpaolo Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials |
title | Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials |
title_full | Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials |
title_fullStr | Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials |
title_full_unstemmed | Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials |
title_short | Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials |
title_sort | systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with covid-19, sars, mers or influenza: a systematic review and meta-analysis of randomised trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719379/ https://www.ncbi.nlm.nih.gov/pubmed/34979235 http://dx.doi.org/10.1016/j.phrs.2021.106053 |
work_keys_str_mv | AT caiazzoelisabetta systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials AT rezigasmaom systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials AT bruzzesedario systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials AT ialentiarmando systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials AT cicalacarla systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials AT clelandjohngf systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials AT guziktomaszj systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials AT maffiapasquale systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials AT pellicoripierpaolo systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials |